NEW
YORK, Sept. 5, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, will participate at the H.C Wainwright
25th Annual Global Investor Conference. Delcath CEO,
Gerard Michel will present on
September 13 at 11:00 AM ET.
A webcast of the presentation will be available at
https://delcath.com/investors/events-presentations/. A replay of
the presentation will be available following the event.
Management is scheduled to host one-on-one meetings throughout
the event. Investors interested in arranging one-on-one meetings
should contact your conference representative. You may also call or
email Ben Shamsian of Lytham
Partners at 646-829-9701, or shamsian@lythampartners.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary products, HEPZATO KIT (melphalan for
Injection/Hepatic Delivery System), approved for use in
the United States by FDA, and
CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic
perfusion (PHP), designated under the medical device regulation for
use in Europe and the United Kingdom, are designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects during a PHP procedure. For
more information regarding HEPZATO KIT and its use, including
Important Safety Information and Boxed Warning, please visit
HEPZATOKIT.com. For more information regarding CHEMOSAT and its
use, please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-at-the-hc-wainwright-25th-annual-investor-conference-on-september-12-and-13-2023-301918196.html
SOURCE Delcath Systems, Inc.